🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Strasbourg, France
NCT05927688 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher risk of cardiovascular diseases. To this end, the general treat-to-target approach, as recommended in the EULAR guidance, may require several successive treatment lines based on updates to the patients' profile and close monitoring as the keystone of its implementation. Regular feedback from patients could be used to fuel such strategies. This feedback can be collected using an ePRO (electronic Patient Reported Outcome). The purpose of this study is therefore to assess patient management using the information provided by patients through e-PROs, which will transfer the data provided by the patient to the physician and will notify the investigators via email whe

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Men or women of at least 18 years of age * Diagnosed with (at least) one of the following autoimmune diseases: * Rheumatoid arthritis (RA) according to the 2010 EULAR/ACR classification criteria, * Gout according to the 2015 EULAR/ACR classification criteria, * Systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria * Sjogren's Syndrome according to the 2016 EULAR/ACR classification criteria * According to local regulations, patient has expressed his/her non-opposition (for France) or has provided written informed consent (for Switzerland and Germany) to participate in the study * Patient has access to the internet, a functioning email address and a mobile phone number * Patient physically and mentally able to use a computer tool connected to the Internet * Only in Switzerland \& Germany : patient is covered by a health insurance plan Exclusion Criteria: * Any neurodegenerative disease that alters cognitive faculties * Refractory cancer * Patients who do not have access to the Internet and/or do not master its use in the context of this protocol * Unwillingness or inability to adhere to study protocol (language barriers, cognitive disorders…) Subject who is compulsorily detained for psychiatric treatment * Patient who cannot be followed for 2 years by the investigating physician * Patient over the age of legal majority who is protected, or deprived of liberty by judicial or administrative decision (vulnerable subject) * Patient with an estimated life expectancy shorter than 1 year
💊

What it tests

  • Therapeutic management following access by the physician to his patient's ePROs
📍

Where

1 site
University Hospital of Strasbourg
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy